December 2023

–  Data from Phase 1/2 EPCORE™ NHL-1 study show patients treated with epcoritamab experienced 82% overall response rates (ORR) including 63% complete response (CR) rates as presented at the 65th American Society of Hematology (ASH) congress–  Follicular lymphoma is the second most co

Magazine made for you.

Featured:

No posts were found for provided query parameters.

Elsewhere: